remetinostat (SHP-141) / Medivir  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
remetinostat (SHP-141) / Medivir
NCT01433731: Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

Checkmark For cutaneous T-cell lymphoma
Dec 2014 - Dec 2014: For cutaneous T-cell lymphoma
Checkmark Cutaneous T-cell lymphoma
Sep 2014 - Sep 2014: Cutaneous T-cell lymphoma
Completed
1b
18
US
placebo for SHAPE (SHP-141), SHAPE (SHP-141) 0.1% BID, SHAPE (SHP-141) 0.5% BID, SHAPE (SHP-141) 1.0% BID
TetraLogic Pharmaceuticals, The Leukemia and Lymphoma Society, Therapeutics, Inc., Veristat, Inc., PPD
Lymphoma, T-Cell, Cutaneous
09/13
09/13

Download Options